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Abstract
Probiotics and prebiotics are microbiota management tools for improved host health.
They target gastrointestinal effects via the gut, although direct application to other
sites such as the oral cavity, vaginal tract and skin are being explored. Here, we
describe gut-derived effects in humans. In the past decade, research on the gut
microbiome has rapidly accumulated, accompanied by increased interest in
probiotics and prebiotics as a means to modulate the gut microbiota. Given the
importance of these approaches for public health, it is timely to reiterate factual and
supporting information on their clinical application and use. In this Review, we
discuss scientific evidence on probiotics and prebiotics, including mechanistic
insights into health effects. Strains of Lactobacillus, Bifidobacterium, and
Saccharomyces have a long history of safe and effective use as probiotics, but
Roseburia spp., Akkermansia spp., Propionibacterium spp. and Faecalibacterium
spp. show promise. For prebiotics, glucans and fructans are well proven with
evidence building on prebiotic effects of other substances (e.g. oligomers of
mannose, glucose, xylose, pectin, starches, human milk; and polyphenols).
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Key Points


The human gut microbiota is integral to health and is associated with a variety
of diseases



Therapeutic and prophylactic effects of some probiotics and prebiotics for a
variety of gut-related disorders might be, at least in part, mediated through
modification of the microbiota and/or its function



Probiotic microorganisms act via a variety of means, including modulation of
immune function, production of organic acids and antimicrobial compounds,
interaction with resident microbiota, interfacing with the host, improving gut
barrier integrity and enzyme formation



Prebiotics are substrates that are selectively utilized by host microorganisms
conferring a health benefit; prebiotic effects include defence against
pathogens, immune modulation, mineral absorption, bowel function,
metabolic effects and satiety



Use of some probiotics and prebiotics is justified by robust assessments of
efficacy, but not all products have been validated; the goal is evidence-based
use by healthcare professionals
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[H1] Introduction
When the Argentinian government requested of the Food and Agriculture
Organization of the United Nations that an expert panel be formed to evaluate the
health and nutritional properties of probiotics in food in 2000, it precipitated the reemergence of a concept long part of human history. International recognition of the
concept of probiotics, and coalescence around a definition of probiotic offered by this
expert consultation,1 established an important consensus foundation.
The definition of probiotic decided by the consultation retained the essence of
historical definitions offered over previous decades. It was intentionally broad, to
encompass a wide variety of microorganisms, hosts, benefits, target sites and
product types. It has stood the test of time and was reaffirmed, but grammatically
corrected, in 2014 to the consensus definition of probiotics, which is: “live
microorganisms that, when administered in adequate amounts, confer a health
benefit on the host”.2
Studies abound that describe how microbes are integrated into life processes
and define ways that beneficial microorganisms—both commensal and externally
applied—affect physiological homeostasis and host function.3 On the horizon is the
promise of newly constructed recombinant strains and promising novel microbial
species, which await testing in vivo. However, as these advances develop, we should
recognize actionable evidence that is currently available. As will be discussed,
convincing evidence exists for some established probiotics, which should be
incorporated into health management. This incorporation includes complementary
use with pharmaceutical agents, foods and lifestyle. Education of consumers,
practitioners and regulators will facilitate appropriate use and point out needs for
further research, which will hopefully include exploration of how to reach the
individuals at greatest need with affordable and reliable probiotic products.4
Prebiotics, first defined in 19955, have been used to manipulate microbes in
the host to improve measurable health outcomes. An update to the prebiotic
definition published in 2017 as “a substrate that is selectively utilized by host
microorganisms conferring a health benefit” was compelled by the need to clarify
what did and did not constitute a prebiotic substance in the face of scientific
advances.6 The desire to optimize, for improved health, the microbial world
associated with us has led to the development of compounds targeting an everexpanding group of microorganisms and benefits that are derived through them. No
longer are prebiotics seen simply as boosters of the growth of bifidobacteria and

3

lactobacilli, with recognition of their effects on system-wide metabolic and
physiological readouts.6 Although the intestine remains the gateway to most of these
effects, it is not an exclusive one. The extent to which prebiotics can affect microbial
communities of the urogenital tract, oral-nasal areas and skin is now the subject of
intensive exploration.7
This Review describes the current understanding of probiotic and prebiotic
mechanisms of action, provides important examples of clinical studies on probiotic
and prebiotic applications, and discusses current knowledge on mechanisms at the
heart of these effects.

[H1] Human gut microbiome
The human gut is predominantly inoculated at birth. Microbial diversity develops as
feeding and dietary patterns mature. It resembles the ‘adult-like’ microbiota after 3-5
years.8 Because of variations in pH, substrate concentration, Eh (redox potential,
activity of electrons) and transit time, microbial numbers vary between different
anatomical regions of the gut.9 The stomach harbours fewer microbes than the small
and large intestines.10 Studies using metagenomic approaches have highlighted the
complex inter-relationship between our resident intestinal microbiota and mammalian
metabolism.11 Through the process of fermentation, anaerobic gut bacteria
metabolise substrates to form end products such as organic acids and gases.12 The
main precursors for fermentations are dietary carbohydrates, proteins and lipids, as
well as indigenous secretions such as mucin. This anaerobic metabolism contributes
positively towards host daily energy requirements and homeostasis in the gut.13
Ideally, the human host lives in harmony with its complex gut microbiota in a state
that promotes physiological resilience.14 However, dysbiosis can result from
challenges such as medications, infections, ageing, lifestyle, surgery and poor
nutrition,14,15
In humans, a range of acute and chronic disorders can be a consequence of
perturbation of gut microbial communities.16-18 On a chronic basis, inflammatory
bowel disease (IBD), obesity and irritable bowel syndrome (IBS) have all been linked
to intestinal bacteria and their activities.10 This aspect opens up the possibility of
influencing the microbiota to reduce disease risk, fortify homeostasis and, in some
cases, improve therapeutic status. Diet is a principal driver of gut fermentation and
therefore can greatly influence functionality of the indigenous microbiota.19 Prebiotics
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are popular dietary approaches for modifying the gut microbiota to improve host
health,6 as they are affordable, effective, safe and accessible.

[H1] Probiotics
As the concept of probiotics evolved over the past decades, the assumption was that
their effects would be mediated through direct interaction with commensal
microbiota. Some early definitions stipulated that probiotics functioned “by
contributing to (the host’s) intestinal microbial balance”20 or “by improving the
properties of the indigenous microflora”.21 However, the current consensus definition
of probiotics does not stipulate that probiotic effects are only microbiota-mediated,
and indeed, other types of mechanisms are known. This idea that probiotics function
in ways that might act beyond affecting the colonizing microbiota opens the door to a
wider range of probiotic possibilities, encouraging innovation in the field.
Much of our knowledge on probiotic mechanisms is based on research using
in vitro, animal, cell culture or ex vivo human models. Figure 1 compiles known
mechanisms distributed among various probiotic strains. Not all mechanisms have
been confirmed in humans nor do they exist in every probiotic strain. Although
multiple mechanisms likely co-express in a single probiotic, the importance of any
given mechanism will depend on many factors. For example, in an inflamed intestine,
the ability to down-regulate inflammatory mediators and increase epithelial barrier
function may be most important,22,23 whereas the ability to increase short chain fatty
acids and hydration in the colon may be more important to normalizing intestinal
motility.24
Research elucidating mechanisms of probiotics often relies on in vitro or
animal studies. Probiotics are not unique in this regard. Animal studies have not
always translated to humans;25 notable examples are probiotics for Crohn’s disease
and mental health function.26,27 Furthermore, inherent difference among probiotic
strains exists, for example in the findings that one probiotic (in this case in
conjunction with a prebiotic) significantly prevented sepsis in infants,28 whereas a
different formulation failed to prevent necrotizing enterocolitis.29
The historic concept of ‘colonization resistance,’30 the situation whereby
native gut microbiota occupy host tissues to exclude infection by potential pathogens
(resident or invading), is another mechanism attributed to probiotics.31 Expression of
colonization resistance is likely a sum outcome of the functioning of many of these
different mechanisms in concert. Indeed, many host factors may impact the ultimate
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expression of health effects imparted by a probiotic, including properties of baseline
microbiota. Although few data exist, one study tracking probiotic persistence in the
gut was linked to properties of the baseline microbiota. Persistence of B. longum
subsp. longum AH1206 in the human gut was predicted by low abundance in the
host of B. longum and low microbial carbohydrate utilization genes.32 No clinical
endpoints were tracked in this study, but the property of long-term persistence may
contribute to physiological benefits. However, results of many different clinical trials
that do not include stratification of subjects by baseline microbiota suggest that
probiotic function is not necessarily predicated on a specific microbiota baseline.33,34
There may well be compositional patterns of microbiota that do not respond well to
incoming probiotic strains, just as there are for certain drugs,35 but such profiles have
not yet been fully defined.
[H3] Modulation of cell-mediated and humoral immune functions. Some
probiotics have been shown to increase phagocytosis or natural killer cell activity and
interact directly with dendritic cells (reviewed in36) Some also demonstrate the ability
to upregulate antibody secretion translating into improved defences against
pathogens and augmenting vaccine responses.37-39 Probiotic strains can increase
levels of anti-inflammatory cytokines such as tumour necrosis factor with implications
for abating colon cancer and colitis.10,36 As discussed later, cell-surface architecture,
such as fimbriae, capsule and surface structures expressed by certain probiotics is a
mechanistic driver for several of these activities.
[H3] Production of organic acids. Probiotic species belonging to the Lactobacillus
and Bifidobacterium genera produce lactic and acetic acid as primary end-products
of carbohydrate metabolism. These organic acids when produced in situ can lower
luminal pH and discourage growth of pathogens as shown in various model
systems.40-42 Lactobacillus and Bifidobacterium do not produce butyrate but through
cross-feeding other commensal microbiota (for example, Faecalibacterium), levels of
butyrate and other short-chain fatty acids in the gut can increase, potentially
influencing many aspects of physiology, including the cardiometabolic phenotype.43
This phenotype can be derived from increased production of butyrate, correlating
with improved insulin response, or abnormalities in propionate linked to type 2
diabetes.44 Based upon analyses of weight, lifestyle, metabolic measurements and
short chain fatty acid (SCFA) levels, the risk of subjects developing cardiometabolic
diseases can be calculated.45
[H3] Interaction with gut microbiota. Probiotic strains can interact with the gut
microbiota through competition for nutrients, antagonism, cross-feeding and support
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of microbiota stability.46 Many probiotic strains are antagonistic toward other
microbes, in part due to saccharolytic metabolism, which produces organic acids, but
also by production of bacteriocins.47 These antimicrobial compounds can be active
against pathogens at many sites including the human urinary tract and in the gut of
humans or animals.48,49 Bifidobacteria produce acetate and can cross-feed other
members of the gut microbiota (reviewed in50). Strains B. longum AH1206 and B.
bifidum-ATCC15696 have been shown to persist in the infant gut,32,51 although in the
latter case the concomitant decrease in pathogen abundance was not tested for a
link to bacteriocin production. The ability of certain probiotic strains to improve
eradication of Helicobacter pylori may involve some inhibition of the pathogen, but
stronger evidence for probiotics in this context is for reducing side effects of
antibiotics used in treatment.52
[H3] Probiotic–host interactions. Interactions of probiotic strains with host tissues
are mediated by cell surface macromolecules, including proteins (surface layer
associated proteins, mucin binding proteins, pili, and LPxGT-binding proteins) and
non-protein components (lipoteichoic acid, peptidoglycan, exopolysaccharides).53
These structures have been shown to affect binding to intestinal and vaginal cells,
mucin, and immune or dendritic cells resulting in increased transit times and
improved barrier integrity (reviewed in53). An example of the different surface
structures can be seen in the genome comparison of L. rhamnosus GG that uses pili
to interact with the intestine and L. rhamnosus GR-1 with a unique cluster of
exopolysaccharides to aid in vaginal activity.54
[H3] Improvement of barrier function. Primarily through studies in cell lines,
several probiotic Lactobacillus and Bifidobacterium strains have been shown to
increase expression of tight junction proteins (reviewed in55). A study using human
intestinal epithelial enteroids and colonoids showed that L. rhamnosus GG pretreatment countered damage to tight junction zonula occludens 1 (ZO-1) and
occludin (OCLN) caused by interferon-gamma.56 Another way in which probiotic
strains may improve barrier function is through upregulating expression of mucus
secretion genes, thereby reducing pathogen binding to epithelial cells.57,58. Downregulating inflammation is also regarded as a factor that improves barrier function.53
Of note, although some probiotic strains have the capacity to improve barrier
function, this does not always occur in every cohort for reasons not yet fully
understood.59
[H3] Manufacture of small molecules with local and non-local effects. Small
molecules produced by certain probiotic strains have been described with different
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effects on the host and its microbiota.58 Perhaps one of the more intriguing findings is
the production of neurochemicals such as oxytocin, gamma-amino butyric acid,
serotonin, tryptamine, norepinephrine, dopamine and acetylcholine (reviewed in60,
61,62

) known to affect brain function. In a rat model of stress, L. helveticus NS8

feeding resulted in lower plasma corticosterone and adrenocorticotropic hormone
levels and restored hippocampal serotonin and norepinephrine.63
[H3] Production of enzymes. Microbial enzymes such as β-galactosidase64 and bile
salt hydrolase,65 which are produced and delivered by some probiotic strains,
improve lactose digestion and blood lipid profiles in humans, respectively. In the case
of Streptococcus thermophilus in yogurt, which facilitates lactose digestion, its
predisposition to be permeabilized by bile when entering the small intestine promotes
the delivery of microbial β-galactosidase to the small intestine to break down lactose
into digestible glucose and galactose.64 This results in clinical benefit to individuals
who are lactose intolerant. Indeed, the European Food Safety Authority considered
evidence of this effect sufficient to authorize a health claim for S. thermophilus and L.
bulgaricus as components of yogurt to alleviate symptoms of lactose maldigestion.66
Admittedly, cause and effect evidence of mechanisms in human hosts
remains to be gathered, but technological advancements in genome sequencing and
microbiome analyses, and surgical advances that allow real-time sampling in vivo,
should help acquire elucidating data over the next few years.

[H1] Prebiotics
If we are to understand how prebiotics work, and more importantly exploit them to
manipulate the microbiota to propagate health, then we need to keep in mind that
microbes live in complex functional ecosystems. Within these, bacteria have a
multitude of roles, including the conversion of incoming dietary carbohydrates,
proteins and some fats into metabolites that can have either positive or negative
effects upon host health.67,68,69,70. Current prebiotics are predominantly
carbohydrate-based, but other substances such as polyphenols and
polyunsaturated fatty acids may exert prebiotic effects.6 An example of polyphenols
is water-insoluble cocoa fraction, shown in a gut model to significantly increase
bifidobacteria, lactobacilli and butyrate production.71
Low molecular weight carbohydrates are very efficiently metabolised by
microorganisms such as bifidobacteria, which possess a range of cell-associated and
extracellular glycosidases and specific transport systems allowing them to rapidly
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assimilate low molecular weight sugars.72,73 Other microbes, such as members of the
Bacteroides genus are adept at breaking down high molecular weight
polysaccharides.74,75 Some bacteria might be regarded as keystone, having the ability
to initiate breakdown of particular substrates;76 for example, Ruminococcus spp. can
facilitate resistant starch degradation.77 Liberated low molecular weight dextrins are
then metabolized by the microbial community. The pathway from a polysaccharide to
a SCFA is thus a complex and indirect network of metabolism. Acetate and lactate,
the main metabolic end products of bifidobacteria and lactic acid bacteria, are utilised
by other microorganisms to produce, for instance, propionate78 and butyrate.50,79
Likely ecological networks involved in the metabolism of carbohydrates have been
elucidated,74,80,81 although the extent to which they operate in the gut is not clear at
the present time.
A further complication in studies of the ecosystem response to carbohydrates
is that it is heavily influenced by the microorganisms that are already present. It has
become clear that individual microbiomes that are Prevotella-dominant can ferment
carbohydrates more rapidly than can Bacteroides-dominant microbiomes.82
Furthermore, when these distinct faecal inocula, dominated by Prevotella or
Bacteroides, were incubated with prebiotic fructo-oligosaccharides (FOS) or with two
different arabinoxylans, the profile of SCFA produced was distinctly different and
correlated with the microbiome.83 Cultures using Prevotella-dominant inocula
produced significantly higher ratios of propionate to acetate and butyrate than the
Bacteroides-dominant microbiotas. A similar influence of starting microbiome
composition on carbohydrate fermentation has been seen using isomaltooligosaccharides as a carbon source in an in vitro batch fermentation model with
human microbiota.84
Microbiome studies based on 16s rDNA sequencing have given rise to an
increased awareness of the richness of the gut microbial ecosystem85 and, in some
cases, to associations between certain microorganisms or microbiome profiles and
disease states. These include IBD,86 type II diabetes mellitus,87-89 IBS90,91 and
obesity.92,93. These profiles have frequently been termed “dysbioses”, although it is
not currently possible to define such a state as ‘normobiosis’ or a ‘normal’ microbiota
Such associations tend to be merely the starting point for investigation into the role of
specific microorganisms in disease. Sequencing studies do not give us an
understanding of the functional interactions between members of the gut microbiota
and it is imperative that this functional ecology is studied in more detail. It is becoming
clear that although there might be a huge diversity of individual taxa in the gut
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microbiomes of individuals, there is a high level of functional redundancy, and specific
ecological functions are provided by a range of bacteria across different
individuals,94,95.
Given that we have an imperfect understanding of the functional ecology of
the gut microbiota, uncovering the mechanisms of action of prebiotics presents a
challenge. Despite this issue, we can postulate probable mechanisms by which a
prebiotic can lead to health benefits. These pathways are presented in Figure 2 and
discussed herein. All of these postulated mechanisms have support from research
carried out through in vitro or animal models, although in many cases, establishing
that they actually occur within human gut microbiota is difficult.
[H3] Defence against pathogens. Although mechanistically challenging to establish
in humans in vivo, pathogen defence can be investigated in vitro using model
systems.96,97. As noted for probiotics, production of organic acids through prebiotic
administration and propagation of beneficial bacteria will result in a reduction in
luminal pH, inhibiting growth of pathogens. Establishment of a stable population of
commensal microorganisms will reduce nutrient availability for invading
microorganisms, inhibiting colonisation. In studies of elderly individuals, 10 weeks of
daily galactooligosaccharide (GOS) intervention induced increases in immune
function, notably enhanced phagocytic activity and activity of natural killer cells.98,99.
[H3] Immune modulation. Although exact mechanisms are unclear, there is
evidence that prebiotic intervention can reduce type 2 T helper responses and thus
affect allergy. The most supportive data come from studies in infants. Galacto- and
long chain fructo-oligosaccharides in infant formula administered in a double-blind,
randomized, placebo-controlled trial of 259 infants, showed reduced incidence of
atopic dermatitis, wheezing and urticaria to less than 50% of the incidence in nonprebiotic formula fed infants.100,101 In a prospective, double blind, placebo-controlled
fashion, not as yet replicated, healthy term infants at risk of atopy fed prebioticsupplemented hypoallergenic formula for 6 months had a greater than five-fold
reduction in prevalence of allergies five years after feeding.102
[H3] Increased mineral absorption. Most absorption of minerals takes place by
active transport mechanisms in the small intestine,103 Scavenging calcium could make
a substantial positive contribution to health. As already discussed, fermentation of
prebiotics leads to production of SCFA, which reduces luminal pH. This drop in pH
can increase calcium solubility, thereby providing a greater driving force for passive
uptake. A problem with proving this is that many calcium salts in supplements and
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food have pH-dependent solubility and limited availability, and depending on the
starting pH, solubility of calcium can actually increase with higher pH.104
Studies have shown that consumption by young adolescents of a mixture of
FOS and inulin105,106 or GOS107 can result in marked increases in absorption and
calcium mineralised into bone. Such early intervention may reduce incidence of
osteoporosis in later in life. This hypothesis is supported by animal model data108, but
long-term studies in humans are lacking.
[H3] Improved bowel function. Improvements in bowel function have often been
ascribed to simple faecal bulking by consumption of dietary fibre. However, animal
studies have shown that SCFAs produced by fermentation of prebiotics can regulate
gut hormones that in turn modulate the local motor responses of the gut109,110. The
humectant water binding capacity of prebiotic carbohydrates also has the effect of
softening stools, making passage easier.111,112
There are surprisingly few studies on the effect of prebiotics on bowel
function, although they have consistently led to improvements in stool consistency
and defecation frequency in randomized trials113,114
[H3] Metabolic effects. As discussed earlier, prebiotic intervention results in the
elaboration of SCFAs that can act to improve barrier function in the gut and prebiotic
intervention with GOS has shown improvements in barrier function in vivo.115 Impaired
barrier function can allow translocation of inflammatory mediators such as bacterial
lipopolysaccharide (LPS) from the gut into systemic circulation, which has been
termed metabolic endotoxaemia116 and has been suggested to be a causative factor
in diabetes and obesity according to evidence, albeit from studies in mice.117, 118.
Metabolic effects of prebiotics have been subject to several metaanalyses119,120,121,122 and although the results among studies vary, the general
consensus is that prebiotic intervention has a positive effect on glucose homeostasis,
inflammation and blood lipid profile in humans. Although interventions with GOS123
and inulin124 have shown improvements in inflammatory markers in individuals with
obesity, these have been relatively short-term studies over a few months and the
effect on metabolic health over a long period of consumption is yet to be established.
The hypothesis underlying much research on prebiotics and barrier function
and inflammation is that fermentation products such as SCFA probably mediate the
beneficial effects through mechanisms discussed above. However, it has been shown
that, at least in vitro, GOS can directly stimulate the expression of tight junction
proteins in intestinal epithelial cell lines and decrease trans-epithelial flux125,126. Given
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that GOS is fermented in the gut, however, the extent to which such mechanisms act
in vivo are unclear at present.
It is possible that the effect of inulin in improving glycaemic response could be
due to direct inhibition of the intestinal isomaltase-sucrase enzyme complex, but so
far the evidence is only from mouse studies127. Identification of direct mechanisms
from metabolic mechanisms in humans is, however, extremely difficult.
[H3] Effect on satiety. SCFAs produced by fermentation in the gut can interact with
specific fatty acid receptors, FFAR2 and FFAR3 and regulate lipolysis and release of
the incretin glucagon-like peptide-1.128,129 These receptors are found on many tissues
and could be a key mechanistic link between prebiotic fermentation and systemic
health benefits. SCFAs can regulate appetite via several mechanisms,130 with studies
showing that the interaction between SCFA and colonic L-cells results in production
of anorexigenic hormones such as PYY and GLP-1. Other examples are SCFAs
surviving metabolism by colonic epithelial cells can reach the liver via the hepatic
portal vein where propionate stimulates gluconeogenesis, acting as a satiety signal.131
SCFAs entering the circulation could also interact with FFAR2 and FFAR3 located on
adipose tissue, resulting in leptin stimulation. According to a study in mice, acetate,
the principal SCFA formed by prebiotic fermentation, can cross the blood-brain barrier
and enter the hypothalamus, promoting anorectic signals.132

[H1] Translation to the clinic
Box. Overcoming barriers to translation to the clinic







More high quality, adequately powered randomized, controlled trials that test
well-defined probiotic (strain or strain combinations, dose, delivery matrix) and
prebiotic interventions on substantive clinical outcomes.
Better tracking of safety data during the conduct of short and long term clinical
trials
Improved availability of high quality, properly labelled, and effective commercial
products133
Application by clinicians of available efficacy data in evidence-based manner.
This comprises assessment of totality of data (positive and null) through unbiased
systematic review processes for specific probiotic and prebiotic interventions.
Better understanding of characteristics of host (including diet, baseline
microbiota, medications and disease) that improve response to probiotics or
prebiotics
Clinicians need clarification about probiotic and prebiotic products: are they safe,
who will benefit – how and to what extent, and can the product labels be trusted
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Many clinical gastrointestinal indications could benefit from probiotic and prebiotic
interventions. In the case of prebiotics, a link between the clinical benefit to
microbiota function should be established. For probiotics, a clinical indication is
needed. For both, robust product information is required133.
There are clinical indications for use of certain probiotic strains supported by
robust evidence. In paediatric and/or adult populations, evidence exists for
necrotizing enterocolitis (NEC),134 antibiotic-associated diarrhea (AAD) and H. pylori
infection135,136,137, defecation frequency138,139, infantile colic,140, mild to moderate
ulcerative colitis,141 irritable bowel syndrome,142 treatment of acute diarrhea143
prevention of C. difficile-associated diarrhea144 and neonatal sepsis.28 A recent metaanalysis provided evidence that probiotic use has the potential to decrease antibiotic
utilization in children.145 Some clinical guidelines have been issued for probiotic use
in children.146,147 Systemic from the gut, evidence exists for reduction of incidence
and duration of upper respiratory tract infections.147,149 No official recommendations
have been made for adult uses of probiotics. Additional research clarifying the most
effective strains and doses is needed for many clinical targets so far
researched.150,151,152 Although many clinical indications are promising, data are still
emerging for endpoints including brain, metabolic, and cardiovascular effects.
Generally, the strength of evidence for prebiotic interventions lags behind
those for probiotics. Perhaps the strongest support for prebiotic use comes from
prebiotic infant formulae. Such products are now routinely supplemented with
mixtures of GOS and fructans153,154 and this blend of prebiotics in a 9:1 ratio reduced
respiratory tract infections to levels found in breast-fed infants.155,156 101 There is less
evidence that prebiotics can reduce infections in adults, although one placebocontrolled, randomized, double blind study of 159 healthy volunteers, showed that
GOS could reduce the incidence of diarrhea.157
Much of the research focus on prebiotics has been in the realm of functional
food (improves well-being through benefit beyond its nutrient content) applications.
The one example of a prebiotic food application recognized by European regulatory
authorities is on improved bowel function in healthy adults resulting from consumption
of 12g of chicory inulin per day.158,159
Prebiotic foods designed to increase satiety and reduce energy intake is a
promising approach to augment compliance with weight loss diets. Oligofructoseenriched inulin in overweight children has been shown to increase satiety, reduce
energy intake as well as BMI and body fat mass over 16 weeks (body weight
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decrease of 3.1%, percent body fat decrease of 2.4% compared with children given
placebo (increase of 0.5%, increase of 0.05% respectively).160,161 Oligofructose
ingested daily by 29 adults for 12 weeks in a granola bar formulation, reduced by 0·3
(sd 1·2) kg lean mass and waist circumference by -2·2 (sd 3·6) cm, with a
concomitant intake and increase satiety in adults over a 12-week intervention.162
However, not all studies have suggested benefits. One study of 97 overweight or
obese children given oligofructose for 12 weeks did not show a statistically significant
change in BMI-for-age z-score versus placebo.163 This study did not measure the
effect of the prebiotic on the gut microbiota and its function, which would have
provided mechanistic insight to better understand the null study results and enabled
better design of future interventions.
The replacement of glycaemic carbohydrates in food products with nonglycaemic carbohydrates to reduce post-prandial glycaemic responses has already
received a positive EFSA opinion.164 Prebiotic carbohydrates might be expected to
bring additional benefits in terms of increasing satiety in such a replacement strategy.
Promising results were observed from a double-blind, randomized, controlled crossover trial of 40-42 healthy adults who consumed a yogurt drink containing
oligofructose. The intervention improved postprandial glucose responses.165
There is now some evidence that the stool microbiota profiles of patients with
inflammatory conditions, such as inflammatory bowel disease, differs from those who
are heathy,166 but it is not clear at the present time why. It is unclear whether these
differences are caused by the underlying medical condition, are a consequence of the
disease pathology, or due to confounding factors such as medications or altered
dietary habits. Probiotic or prebiotic interventions hold promise to achieve disease or
symptom mitigation through microbiota modulation. An understanding of the
microbiome composition and function in the donor and recipient will help us
understand the extent to which clinical success depends on these factors.167 Indeed,
some clinical trials have noted the importance of baseline microbiota composition
among responders.168,169,170 Microbiota patterns can be influenced by lifestyle, living
conditions, diet, medications and stool consistency, among other transient variables.
Advanced age is also thought to be a factor, but one study of Chinese subjects has
shown that healthy centenarians have similar microbiota to healthy young people,171
suggesting that factors other than age are more important drivers of microbiota
composition. Furthermore, research methodologies and data management may lead
to spurious interpretations of microbiota assessments, which has the potential to
mislead.172 Although clinical benefits have been observed with probiotic and prebiotic
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interventions, the onus is on researchers to clarify the role of the microbiome in these
successes to optimize short and long-term outcomes.173,174,175,176,177.
Careful phenotypic and genotypic descriptions of study subjects may also be
important to clinical trial success targeting the microbiome. Host genetic studies may
help, for example, in the microbiome-mediated disease of IBD, where 163 loci were
identified to meet genome-wide significance thresholds.178 However, since the
majority of cases of IBD are not the result of a single host gene defect,179
complicating the development of clinical interventions based on host genetics.
Another complication is that identified genes constitute risk factors, not causal
determinants, for a disease, and therefore clinical strategies based on host genomics
have not been forthcoming.
IBD comprises two main forms, Crohn’s disease and ulcerative colitis. In
Crohn’s disease, there seems to be distinct molecular subclasses of genomic
associations, further complicating development of effective strategies.180 This may in
part explain why probiotic strains have mostly failed to be effective in improving the
management of Crohn’s disease.181,182 The reason why mild to moderate ulcerative
colitis has been somewhat improved by probiotic intervention183 but Crohn’s is not
known. The future success of microbiota manipulation to mitigate serious
inflammatory conditions will require an understanding of the interactions between the
microbiome and the human genetic risk factors and will necessitate moving beyond
microbial genomic sequencing to transcriptomic, metabolomic and proteomic
investigations.
The promise of treating or curing disease with microbiota manipulation
continues to be explored using probiotic species different from those traditionally
employed184. Many probiotics in current use are from the genera Lactobacillus and
Bifidobacterium. Although many of them were derived from the faeces or intestinal
mucosa of healthy human subjects, researchers today are considering the utility of
many newly explored human resident microbes, such as Akkermansia, Eubacterium,
Propionibacterium, Faecalibacterium and Roseburia. This will require going beyond
laboratory animal experiments that proliferate in the literature.185,62
Faecal microbial transplantation (FMT), which has been a reasonably
successful treatment for recurrent Clostridium difficile infection,186,187,188 is being met
with mixed success in the treatment of other conditions189-191. Although FMT is not a
probiotic application since it is not suitably defined microbiologically to meet the
probiotic definition,2 the approach is based on the concept that microbes derived
from healthy donor feces can restore proper function to a dysbiotic microbial
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ecosystem. It is noteworthy that there have only been a few blinded, randomized
controlled trials (RCTs) on FMT for treatment of recurring C. difficile, and these have
been relatively small studies and we have little information on the long-term changes
that such a broad, poorly defined and non-specific treatment might have on
individuals. A well-defined reproducible probiotic intervention is more suitable for
rigorous research investigation and could be safer long-term than FMT, as suggested
by several researchers attempting to assemble a defined consortium of microbes for
such purposes 192. Whether these defined consortia, typically comprising many
human commensal microbial species, can reach the same levels of cure as FMT
remains to be seen.
The potential impact of gut microbiota manipulation on clinical medicine is
promising. However, in the excitement over potential, stakeholders often forget that
association does not mean causation. For example, blinded reviews of 34
oesophageal biopsy samples found that these microbiomes could be classified into 2
types. Type I was dominated by the genus Streptococcus and was phenotypically
normal. But Type II, demonstrating a greater proportion of Gram-negative anaerobes
and/or microaerophiles, correlated with oesophagitis and Barrett oesophagus.150 Like
many other microbiome findings, this does not prove causation and there are
numerous potential reasons why these associations might exist, including diet, drugs,
and lifestyle. One hypothesis might be that administering a safe, select
Streptococcus could reduce oesophagitis and Barrett's oesophagus, but this has not
been tested. Microbiome differences do not necessarily mean that microbiota
modification will lead to improved health.

[H1] The future
The gut microbiota might be central to the cause of many disorders and its
modulation could hold the key to new effective therapies. So, what are the roles of
probiotics and prebiotics? In a general sense, both interventions serve to increase
the community of beneficial microorganisms and products of their growth and
metabolism in the host. In this context, effects relayed might exert influences
systemically, such as in the cardiovascular system, or to the urogenital tract, skin and
brain.193
The field is poised for conceptual advances. Target microbes will expand
beyond the typical Bifidobacterium spp. and Lactobacillus spp. (as mentioned above)
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to include other genera and maybe more yeast species.194-197 These microorganisms
might be new probiotic candidates or further targets for prebiotic utilization.
Improved precision, accuracy, and repeatability of measures of microbial
composition, which lead to genuine and not misleading interpretations, are needed in
this field.172 Improved assessments will lead to an expanded range of probiotic and
prebiotic products. For example, propionate and butyrate are both considered to be
beneficial gut microbial metabolites, but neither is produced by bifidobacteria or
lactobacilli.198,199 Therefore, an opportunity exists to define microbes with metabolic
capabilities beyond those afforded by traditional probiotics.
Another development could be anti-adhesive molecules and carbohydrates
that attenuate microbial virulence. These factors would be adjuncts to current
prebiotic approaches in that they are not selectively utilized substrates.
To have robust proof that gut microbiome alterations can reduce disease
incidence or mitigate disease, more well-designed RCTs are needed. By randomly
assigning individuals to intervention groups, most biases are reduced and the
chances of useful results are improved. Due to the easy availability and relatively
cheap cost of high-throughput sequencing technology, microbiota analysis is
becoming widespread and differences among disease states increasingly well
publicized. The expertise and databases required for metabolomic analysis is also on
an upward trend. This will be vital to optimise clinical translation, as a much greater
awareness of the functional ecology of the gut is needed together with improved
clarity of how this ecosystem influences systemic health. Microbiota and host
transcriptomic studies are also important, but they are expensive, time-consuming
and require substantial bioinformatic support. Ultimately, the application of probiotic
and prebiotic regimens has the potential to improve human health and contribute
greatly to how patients are managed and/or disease risk is reduced.
[H1] Conclusions
Although certain commonalities allow us to group substances under the ‘probiotic’ or
‘prebiotic’ umbrellas, benefits to human health are tied to specific products, not the
categories en masse. To the extent that a clinical outcome is associated with a
specific mechanism of action, then it could be hypothesized that a similar strain or
prebiotic expressing that mechanism might also be beneficial. However, it is
important not to overgeneralize conclusions about specific entities. In general, when
an intervention is effective or ineffective, it must be recognized that those results are
tied to specific formulations, doses, clinical endpoints and target populations. It is

17

incumbent upon responsible scientists to consider the totality of available information
on specific interventions as a basis of overall conclusions on effectiveness.
Furthermore, clinicians should scrutinize both positive and null studies for bias, as
only in eliminating bias in research will we move the field toward truth, thereby
realising the potential of probiotics and prebiotics.
The body of research suggests that these interventions can not only improve
symptomology, but have a meaningful effect on reducing pathology and even saving
lives. The prevention of sepsis and NEC in infants provides compelling examples.
These findings demonstrate effective translation of human microbiome research.
Such clinical impact has changed practice in many healthcare environments. Yet
many constituencies have yet to embrace the concept through critically considering
the strengths and weaknesses of existing data.
In developing countries, probiotics widely available in developed countries are
either not accessible or affordable to most people. However, a program has
introduced inexpensive sachets containing a probiotic L. rhamnosus (GR-1 or Yoba
2012) plus S. thermophilus C106 that allows locals to produce different forms of
fermented foods (yoghurt, millet, cereals, juices) that not only influence health but
also empower poverty-stricken communities to improve social well-being.4 With over
260,000 consumers being reached each week in East Africa, the potential is
enormous to use these beneficial microbes and local food sources to impact
communities (manuscript submitted).
Diseases and poor health often result from the interplay of microbiological
and biological ecosystems along with societal issues including pollution, food
shortages and poor medical care.200,201 We encourage more research and
translational efforts on probiotics and prebiotics to serve the people of developing
countries, who might stand to benefit most from these interventions.
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Figure 1. Probiotic mechanisms of action. Diverse mechanisms are likely to drive
probiotic benefits to host health. In some cases, such as production of antimicrobial
products and cross-feeding other resident microbes, these mechanisms are driven
directly by interactions with the resident microbiota. In other cases, such as direct
interaction with immune cells, their effects might be directly via interaction with host
cells. Overall, clinical benefits delivered by probiotics could result from the combined
action of several mechanisms.
GABA, gamma amino butyric acid.

Figure 2. Identified mechanisms of action of prebiotics
The premise is that prebiotics enter the gut and are selectively utilized. This step
increases bacterial growth and functionality of specific genera or species. As a result
of either or both of these effects, health benefits can then accrue. Fecal bulking and
improved bowel habits occurs due to microbial growth. Immune regulation can be
influenced by increased biomass and cell wall components of the bacteria. Metabolic
products include organic acids, which lowers intestinal pH and have concomitant
effects upon microbial pathogens and mineral absorption. Metabolic products can also
influence epithelial integrity and hormonal regulation. Bacteria that respond to prebiotic
intake can influence the microbiota composition through elaboration of antimicrobial
agents (e.g. peptides) and competitive interactions, possibly reducing infections and
bacteria containing LPS.
GLP, glucagon like peptide; IL – interleukin; LPS, lipopolysaccharide; PYY, peptide
YY; TGF, transforming growth factor; Th1, type 1 T-helper cell, type 1; Th2, type 2-T
helper cell; Tr, regulatory T cell.
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